Already on ArticleSlash?

Forgot your password? Sign Up

Several Monoclonal antibody IMC-11F8 is able to selectively kill tumor cells

 


Visitors: 4,308
 10 votes

Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor. The trastuzumab not only for make the cell surface expression of Her-2 down, but also make it be combined with with the Her-2 ECD shedding from the plasma membrane free, and inhibition of proliferation-promoting activity of Her-2 cells. In addition, The trastuzumab may effectively stop Her-2 extracellular domain shedding from the cell surface. The trastuzumab is no activity for the low level of Her-2 expression in cancer patients, but also have the effect of only 1 / 3 of patients in Her-2 overexpressing breast cancer patients.

Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. The new anti-Her-2 antibody Pertuzumab represents combined with Her-2 receptor extracellular domain zone Ⅱ to stop the formation of dimers and thus Inhibit receptor-mediated signaling pathways. It may explains part of the reason of Pertuzumab represents inhibition of Her-2 low levels of tumor growth, Pertuzumab represents are combined with Her-2 receptor extracellular Ⅳ area, Dimer formation Does not involve Ⅳ area. Therefore, trastuzumab only Her-2 overexpressing breast cancer patients effectively.

The positive rate of EGFR is different in various tumor tissues, it is closely related with the Degree of tumor differentiation and malignancy and infiltration. The Cetuximab to inhibit the action of Phosphorylation and activation of receptor kinase by blocking EGFR ligand binding and inhibits proliferation of human pulmonary adenocarcinoma cells in culture.

Other anti-EGFR monoclonal antibody therapeutic monoclonal antibody include Jesper, round the source of the monoclonal antibody IMC-11F8, identify the EGFR variant EGFRvIII monoclonal antibody mAb 806 and so on.

Researchers are currently recruiting mesothelioma patients for a Phase II study that is aimed to test the safety and effectiveness of IMC-A12 in patients who have previously been treated with standard chemotherapy methods. Researchers are currently recruiting mesothelioma patients for a Phase II study that is aimed to test the safety and effectiveness of IMC-A12 in patients who have previously been treated with standard chemotherapy methods. IMC-A12 is an antibody that is designed to block the effects of a protein called Type I Insulin-Like Growth Factor (IGF-1R), which is thought to play a role in helping cancer cells grow and divide. IMC-A12 is a new cancer treatment that has not yet been approved by the U. S. Food and Drug Administration.

the article from:Curative medicine and health site

(413)

Article Source:


 
Rate this Article: 
 
Oncocytoma A Kidney Tumor
Rated 4.4 / 5
based on 10 votes
ArticleSlash

Related Articles:

Monoclonal Antibody - Alternatives for Treating Non-Hodgkin's Lymphoma

by: Groshan Fabiola (January 19, 2007) 
(Cancer)

Eating Cabbage and Brussels Sprouts Can Kill Cancer Cells

by: Pauline Go (December 07, 2008) 
(Cancer)

Stem Cells - The Master Cells of Human Body

by: Melvin Ngiam (August 06, 2008) 
(Reference and Education/Science)

Selectively Laying Horses to Lose is Still an Effective Strategy

by: Jason Towse (July 08, 2008) 
(Recreation and Sports/Horse Racing)

Cord Blood Cells - Advantages Of Extracting Stem Cells From Umbilical Cord

by: Apurva Jain (June 23, 2007) 
(Health and Fitness)

Understanding Stem Cells STEM CELLS THE FUTURE OF SCIENCE

by: Vipul Jain Advancells (July 08, 2015) 
(Health and Fitness/Healthcare Systems)

HHO Fuel Cells For Cars Do Fuel Cells Really Work?

by: John K Long (June 16, 2008) 
(Automotive)

Gestational Trophoblastic Tumor

by: Milos Pesic (June 22, 2008) 
(Cancer/Skin Cancer)

How To Detect a Malignant Tumor

by: Ezenwaka Chidi (November 03, 2008) 
(Cancer)

Oncocytoma A Kidney Tumor

by: Mc Raflesia (July 19, 2008) 
(Health and Fitness/Diseases)